In the past week, APGE stock has gone down by -15.97%, with a monthly decline of -16.66% and a quarterly plunge of -11.37%. The volatility ratio for the week is 7.05%, and the volatility levels for the last 30 days are 6.70% for Apogee Therapeutics Inc The simple moving average for the past 20 days is -19.67% for APGE’s stock, with a -14.14% simple moving average for the past 200 days.
Is It Worth Investing in Apogee Therapeutics Inc (NASDAQ: APGE) Right Now?
The 36-month beta value for APGE is also noteworthy at 2.68. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 6 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APGE is 36.26M, and at present, short sellers hold a 18.78% of that float. The average trading volume of APGE on November 22, 2024 was 402.15K shares.
APGE) stock’s latest price update
Apogee Therapeutics Inc (NASDAQ: APGE) has seen a decline in its stock price by -4.84 in relation to its previous close of 45.04. However, the company has experienced a -15.97% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-18 that Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
Analysts’ Opinion of APGE
Many brokerage firms have already submitted their reports for APGE stocks, with BofA Securities repeating the rating for APGE by listing it as a “Buy.” The predicted price for APGE in the upcoming period, according to BofA Securities is $80 based on the research report published on May 10, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see APGE reach a price target of $43. The rating they have provided for APGE stocks is “Buy” according to the report published on December 20th, 2023.
Wedbush gave a rating of “Outperform” to APGE, setting the target price at $40 in the report published on August 08th of the previous year.
APGE Trading at -21.27% from the 50-Day Moving Average
After a stumble in the market that brought APGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.71% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 7.05%, as shares sank -17.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.87% lower at present.
During the last 5 trading sessions, APGE fell by -15.97%, which changed the moving average for the period of 200-days by +16.31% in comparison to the 20-day moving average, which settled at $53.35. In addition, Apogee Therapeutics Inc saw 53.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APGE starting from Dambkowski Carl, who sale 6,665 shares at the price of $59.12 back on Nov 06 ’24. After this action, Dambkowski Carl now owns 267,463 shares of Apogee Therapeutics Inc, valued at $394,041 using the latest closing price.
HENDERSON MICHAEL THOMAS, the Chief Executive Officer of Apogee Therapeutics Inc, sale 15,000 shares at $59.22 during a trade that took place back on Nov 06 ’24, which means that HENDERSON MICHAEL THOMAS is holding 1,339,487 shares at $888,320 based on the most recent closing price.
Stock Fundamentals for APGE
The total capital return value is set at -0.24. Equity return is now at value -25.65, with -24.39 for asset returns.
Currently, EBITDA for the company is -83.98 million with net debt to EBITDA at 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.39.
Conclusion
In summary, Apogee Therapeutics Inc (APGE) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
